ArticleFrontiers in pharmacology2025
Reproductive and developmental safety assessment of Ashwagandha (
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of Ashwagandha on Reproductive Health: A Systematic Review of Sex-Specific Hormonal and Fertility Outcomes.Phytotherapy research : PTR · 2026Pooled it
- Efficacy and safety of Ashwagandha (Frontiers in global women's health · 2026Trial
- Evaluating the Safety of Ashwagandha as a Food Additive: A Focus on Reproductive, Thyroid, and Immune System Effects.Phytotherapy research : PTR · 2026Review
- Safety Evaluation of an Aqueous Root and Leaf Extract of Ashwagandha ( Withania somnifera ).Phytotherapy research : PTR · 2026Article
- The Clinical Implications of Ashwagandha (Nutrients · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ashwagandha ( Methods: Animals were housed in polypropylene cages with males and females together during the pre-exposure and pre-mating periods. During the mating phase, one male and one female were kept together until confirmation of pregnancy. Pregnant females were housed individually during the post-mating period and lactating phase, while male rats were returned to their group cages. The procedure used was based on OECD Guideline 421 (OECD, 2016). Results: The No Observed Adverse Effect Level (NOAEL) in adult rats was 2,000 mg/kg. The mean body weights of pups and parental animals were similar (p > 0.05) in the treatment and control arms. Also, the weight of reproductive organs in parental male and female rats was similar (p > 0.05) in all groups. Discussion: The parameters such as T4 and TSH levels, body weight, and weight of reproductive organs in adult Wistar rats and pups, were within range even at the maximum dosage. No evidence of toxicity at various stages of development and reproduction with aqueous extract was observed when administered orally. Rats' ability to reproduce and develop was unaffected by standardized ashwagandha root extract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.